184.71
price up icon0.49%   0.90
 
loading
Precedente Chiudi:
$183.81
Aprire:
$184
Volume 24 ore:
331.61K
Relative Volume:
0.91
Capitalizzazione di mercato:
$19.68B
Reddito:
$3.32B
Utile/perdita netta:
$-860.46M
Rapporto P/E:
-22.20
EPS:
-8.32
Flusso di cassa netto:
$-1.04B
1 W Prestazione:
+0.00%
1M Prestazione:
+0.00%
6M Prestazione:
-13.20%
1 anno Prestazione:
+24.33%
Intervallo 1D:
Value
$183.91
$187.42
Intervallo di 1 settimana:
Value
$183.91
$187.42
Portata 52W:
Value
$141.31
$248.16

Beigene Ltd Adr Stock (BGNE) Company Profile

Name
Nome
Beigene Ltd Adr
Name
Telefono
13459494123
Name
Indirizzo
C/O MOURANT GOVERNANCE SERVICES (CAYMAN), GRAND CAYMAN
Name
Dipendente
10,000
Name
Cinguettio
@beigeneusa
Name
Prossima data di guadagno
2024-11-12
Name
Ultimi documenti SEC
Name
BGNE's Discussions on Twitter

Confronta BGNE con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
BGNE
Beigene Ltd Adr
184.71 19.68B 3.32B -860.46M -1.04B -8.32
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.84 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
602.64 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
614.76 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.56 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
244.90 24.70B 3.81B -644.79M -669.77M -6.24

Beigene Ltd Adr Stock (BGNE) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-04-07 Iniziato RBC Capital Mkts Outperform
2025-03-03 Aggiornamento BofA Securities Neutral → Buy
2024-12-03 Ripresa Morgan Stanley Overweight
2024-09-18 Iniziato JMP Securities Mkt Outperform
2024-02-06 Ripresa JP Morgan Overweight
2023-09-12 Iniziato Macquarie Outperform
2023-08-17 Iniziato Jefferies Buy
2023-07-17 Iniziato Citigroup Buy
2023-06-30 Downgrade Bernstein Outperform → Mkt Perform
2023-01-12 Iniziato Daiwa Securities Buy
2022-10-13 Aggiornamento Guggenheim Neutral → Buy
2022-10-13 Aggiornamento SVB Leerink Mkt Perform → Outperform
2022-08-09 Ripresa JP Morgan Overweight
2022-03-17 Downgrade SVB Leerink Outperform → Mkt Perform
2022-02-07 Iniziato Deutsche Bank Buy
2021-10-12 Iniziato Bernstein Outperform
2021-10-06 Aggiornamento CLSA Underperform → Buy
2021-03-08 Iniziato China Renaissance Buy
2021-03-01 Downgrade CLSA Outperform → Underperform
2020-11-09 Downgrade Ladenburg Thalmann Buy → Neutral
2020-11-06 Downgrade Maxim Group Buy → Hold
2020-11-06 Downgrade Piper Sandler Neutral → Underweight
2020-07-10 Downgrade CLSA Buy → Outperform
2020-03-13 Aggiornamento Macquarie Underperform → Neutral
2020-02-18 Ripresa Goldman Buy
2020-01-17 Aggiornamento CLSA Outperform → Buy
2020-01-17 Ripresa Morgan Stanley Overweight
2019-12-16 Downgrade Guggenheim Buy → Neutral
2019-12-16 Downgrade Piper Jaffray Overweight → Neutral
2019-11-19 Downgrade UBS Buy → Neutral
2019-11-13 Downgrade CLSA Buy → Outperform
2019-11-04 Reiterato Maxim Group Buy
2019-06-04 Iniziato Bernstein Outperform
2019-05-10 Aggiornamento CLSA Outperform → Buy
2019-03-15 Iniziato BofA/Merrill Buy
2019-01-04 Downgrade CLSA Buy → Outperform
2018-11-21 Iniziato JP Morgan Overweight
2018-09-25 Iniziato Leerink Partners Outperform
2018-05-17 Reiterato Maxim Group Buy
Mostra tutto

Beigene Ltd Adr Borsa (BGNE) Ultime notizie

pulisher
Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025
pulisher
Apr 24, 2025

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now? - Yahoo Finance

Apr 24, 2025
pulisher
Apr 23, 2025

Why Summit Therapeutics Rocketed Double-Digits Today - The Motley Fool

Apr 23, 2025
pulisher
Apr 21, 2025

BigBear.ai Holdings Inc (BBAI) gets rating Downgrade from Northland Capital - knoxdaily.com

Apr 21, 2025
pulisher
Apr 21, 2025

Morgan Stanley analysts upgrades an Equal-weight rating for Urban Edge Properties (UE) - knoxdaily.com

Apr 21, 2025
pulisher
Apr 21, 2025

RBC Capital Mkts initates BeiGene Ltd. ADR (ONC) rating to an Outperform - knoxdaily.com

Apr 21, 2025
pulisher
Apr 17, 2025

BGNE Page Not Found - Benzinga

Apr 17, 2025
pulisher
Apr 16, 2025

Beigene’s Wang Xiaodong sells $10.1m in stock By Investing.com - Investing.com India

Apr 16, 2025
pulisher
Apr 16, 2025

Beigene’s Wang Xiaodong sells $10.1m in stock - Investing.com

Apr 16, 2025
pulisher
Apr 16, 2025

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)? - Yahoo Finance

Apr 16, 2025
pulisher
Apr 10, 2025

Permian Resources Corp [PR] Director makes an insider purchase of 250,000 shares worth 3.02 million. - knoxdaily.com

Apr 10, 2025
pulisher
Apr 07, 2025

RBC Capital sets BeiGene stock Outperform with $312 target By Investing.com - Investing.com South Africa

Apr 07, 2025
pulisher
Apr 07, 2025

RBC Capital sets BeiGene stock Outperform with $312 target - Investing.com

Apr 07, 2025
pulisher
Apr 04, 2025

JMP reiterates BeiGene stock with $348 target despite trial halt - Investing.com India

Apr 04, 2025
pulisher
Apr 03, 2025

Beigene’s president Wu Xiaobin sells $14.6 million in shares - Investing.com

Apr 03, 2025
pulisher
Apr 03, 2025

Beigene’s president Wu Xiaobin sells $14.6 million in shares By Investing.com - Investing.com India

Apr 03, 2025
pulisher
Mar 31, 2025

Macquarie Prefers Biotechs Over CDMOs; Top Picks BEIGENE/ AKESO - AASTOCKS.com

Mar 31, 2025
pulisher
Mar 20, 2025

Beigene director Wang Xiaodong sells $10.9 million in shares By Investing.com - Investing.com South Africa

Mar 20, 2025
pulisher
Mar 20, 2025

Beigene director Wang Xiaodong sells $10.9 million in shares - Investing.com India

Mar 20, 2025
pulisher
Mar 18, 2025

Beigene’s Wu Xiaobin anticipates $1.06 million from RMB shares sale - Investing.com

Mar 18, 2025
pulisher
Mar 13, 2025

Bernstein raises BeiGene stock price target to $259 - Investing.com

Mar 13, 2025
pulisher
Mar 12, 2025

BeiGene CEO John Oyler sells $10 million in shares - Investing.com India

Mar 12, 2025
pulisher
Mar 08, 2025

Beigene CEO John Oyler sells $10.39 million in shares By Investing.com - Investing.com South Africa

Mar 08, 2025
pulisher
Mar 08, 2025

Beigene CEO John Oyler sells shares worth $14.6 million - Investing.com India

Mar 08, 2025
pulisher
Mar 08, 2025

BeiGene Stock: Top Executives Sell Shares Near Record High - Sharewise

Mar 08, 2025
pulisher
Mar 07, 2025

Beigene CEO John Oyler sells shares worth $14.6 million By Investing.com - Investing.com South Africa

Mar 07, 2025
pulisher
Mar 07, 2025

Beigene’s president Wu Xiaobin sells $13.6 million in shares By Investing.com - Investing.com South Africa

Mar 07, 2025
pulisher
Mar 07, 2025

Beigene CEO John Oyler sells $10.39 million in shares - Investing.com

Mar 07, 2025
pulisher
Mar 07, 2025

BeiGene Ltd. Sponsored ADR to Host Earnings Call - ACCESS Newswire

Mar 07, 2025
pulisher
Mar 06, 2025

Beigene chair Wang Xiaodong sells shares worth over $2 million - Investing.com India

Mar 06, 2025
pulisher
Mar 04, 2025

Beigene president sells economic interest in RMB shares for $1.16 million - Investing.com India

Mar 04, 2025
pulisher
Mar 04, 2025

BOCOMI: BEIGENE (06160.HK) Guides to Positive 2025 Operating Profit; Rating Kept at Buy - AASTOCKS.com

Mar 04, 2025
pulisher
Mar 03, 2025

JPMorgan maintains BeiGene stock Overweight rating, $311 target - Investing.com India

Mar 03, 2025
pulisher
Mar 03, 2025

Beigene SVP sells $331,375 in American depositary shares By Investing.com - Investing.com South Africa

Mar 03, 2025
pulisher
Mar 03, 2025

Beigene SVP sells $331,375 in American depositary shares - Investing.com India

Mar 03, 2025
pulisher
Mar 03, 2025

JPMorgan maintains BeiGene stock Overweight rating, $311 target By Investing.com - Investing.com South Africa

Mar 03, 2025
pulisher
Mar 03, 2025

BofA lifts BeiGene stock rating, raises target to $320 - Investing.com India

Mar 03, 2025
pulisher
Mar 03, 2025

BofA lifts BeiGene stock rating, raises target to $320 By Investing.com - Investing.com South Africa

Mar 03, 2025
pulisher
Mar 01, 2025

Beigene directors Julian and Felix Baker sell $190m in shares - Investing.com India

Mar 01, 2025
pulisher
Feb 28, 2025

BeiGene gets FDA Orphan Drug Designation for sonrotocla - Investing.com

Feb 28, 2025
pulisher
Feb 28, 2025

Guggenheim lifts BeiGene stock target to $348, maintains Buy rating - Investing.com India

Feb 28, 2025
pulisher
Feb 28, 2025

Guggenheim lifts BeiGene stock target to $348, maintains Buy rating By Investing.com - Investing.com South Africa

Feb 28, 2025
pulisher
Feb 28, 2025

Citizens JMP lifts BeiGene stock target to $348 on strong sales By Investing.com - Investing.com South Africa

Feb 28, 2025
pulisher
Feb 28, 2025

Citizens JMP lifts BeiGene stock target to $348 on strong sales - Investing.com India

Feb 28, 2025
pulisher
Feb 27, 2025

AASTOCKS Financial NewsBeiGene, Ltd. (ONC) - AASTOCKS.com

Feb 27, 2025
pulisher
Feb 27, 2025

UBS Lifts BEIGENE (06160.HK) TP to $330, Rating Buy - AASTOCKS.com

Feb 27, 2025
pulisher
Feb 27, 2025

CLSA Expects BEIGENE to Achieve Operating Breakeven This Yr; TP Sharply Raised to $209.8 - AASTOCKS.com

Feb 27, 2025
pulisher
Feb 27, 2025

BeiGene stock price target raised to $334 at TD Cowen By Investing.com - Investing.com South Africa

Feb 27, 2025
pulisher
Feb 27, 2025

BeiGene stock price target raised to $334 at TD Cowen - Investing.com

Feb 27, 2025
pulisher
Feb 27, 2025

BeiGene stock target raised to $308 on strong FY results - Investing.com India

Feb 27, 2025

Beigene Ltd Adr Azioni (BGNE) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
$32.20
price up icon 0.53%
$69.69
price up icon 1.06%
$20.59
price up icon 0.24%
Capitalizzazione:     |  Volume (24 ore):